Roche, which put billions on the line a year ago across several ADC pacts, kicked off 2025 by returning to Innovent Biologics ...

Oxford BioTherapeutics (OBT) has lined up another big pharma partner for its drug discovery platform, agreeing to work with Roche on the hunt for new antibody therapeutics for cancer in a deal worth ...

Oxford Biotherapeutics Ltd. is partnering with Roche AG to expand the current field of tumor antigens that can be drugged with antibodies, as part of a potential $1 billion-plus agreement. The ...

An Oxford researcher found a rare ... And experts are celebrating the discovery as an early example of the ways that Shakespeare’s work has been adapted to meet a charged moment.